Efficacy and Safety of Gefapixant (MK-7264) in Adult Participants With Recent Onset Chronic Cough (MK-7264-043)
Public ClinicalTrials.gov record NCT04193202. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 3b Randomized, Double-blind, Placebo Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Gefapixant in Adult Participants With Recent Onset Chronic Cough
Study identification
- NCT ID
- NCT04193202
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 3
- Lead sponsor
- Merck Sharp & Dohme LLC
- Industry
- Enrollment
- 419 participants
Conditions and interventions
Conditions
Interventions
- Gefapixant Drug
- Placebo Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- May 20, 2020
- Primary completion
- Oct 18, 2021
- Completion
- Nov 2, 2021
- Last update posted
- May 15, 2023
2020 – 2021
United States locations
- U.S. sites
- 15
- U.S. states
- 13
- U.S. cities
- 15
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Pulmonary Associates, PA ( Site 0016) | Phoenix | Arizona | 85032 | — |
| Center for Clinical Trials, LLC ( Site 0035) | Paramount | California | 90723 | — |
| Springfield Clinic, LLP ( Site 0018) | Springfield | Illinois | 62703 | — |
| Chesapeake Clinical Research, Inc ( Site 0037) | White Marsh | Maryland | 21162 | — |
| Albuquerque Clinical Trials ( Site 0030) | Albuquerque | New Mexico | 87102 | — |
| Montefiore Einstein Center ( Site 0022) | The Bronx | New York | 10461 | — |
| American Health Research ( Site 0047) | Charlotte | North Carolina | 28277 | — |
| Clinical Research Institute of Southern Oregon, PC ( Site 0028) | Medford | Oregon | 97504 | — |
| Northwest Research Center ( Site 0039) | Portland | Oregon | 97202 | — |
| AAPRI Clinical Research Institute ( Site 0051) | Lincoln | Rhode Island | 02865 | — |
| Allergic Disease and Asthma Center ( Site 0027) | Greenville | South Carolina | 29607 | — |
| Diagnostics Research Group ( Site 0021) | San Antonio | Texas | 78229 | — |
| Allergy & Asthma Center ( Site 0001) | Waco | Texas | 76712 | — |
| Tidewater Physician Multispecialty Group, PC ( Site 0048) | Williamsburg | Virginia | 23188 | — |
| Bellingham Asthma & Allergy ( Site 0011) | Bellingham | Washington | 98225 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 76 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT04193202, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted May 15, 2023 · Synced Jul 21, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT04193202 live on ClinicalTrials.gov.